No data available for drug.
Dosing & Uses
Drug Interaction
Adverse Reaction
Actions and Spectrum
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Administration
Patient Information Leaflet
DRUG INTERACTION
No drug interaction found for ponesimod and .
Contraindicated
agmatine
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
mibefradil
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
donepezil (Rx)
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
rivastigmine
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
labetalol
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
agmatine
may have an increased bradycardic effect when combined with ponesimod
mibefradil
may have an increased bradycardic effect when combined with ponesimod
donepezil (Rx)
may have an increased bradycardic effect when combined with ponesimod
rivastigmine
may have an increased bradycardic effect when combined with ponesimod
labetalol
may have an increased bradycardic effect when combined with ponesimod
mibefradil
may have an increased bradycardic effect when combined with ponesimod
indoramin
may have an increased bradycardic effect when combined with ponesimod
minoxidil topical
may have an increased bradycardic effect when combined with ponesimod
tolazoline
may have an increased bradycardic effect when combined with ponesimod
calfactant
may increase the bradycardic effect of bradycardia, causing agents
tizanidine
may increase the bradycardic effect of bradycardia, causing agents
Serious Use Alternative
inamrinone
It may enhance effects when combined with inamrinone by pharmacodynamic synergism
etoposide
when both drugs are combined, there may be a decreased metabolism of etoposide
vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
paclitaxel
when both drugs are combined, the metabolism of paclitaxel decreases when compared with ponesimod
carmustine
when both the drugs are combined, the risk or severity of adverse effects increases
elotuzumab
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
lenvatinib
QTc interval of one another increases on taking ponesimod and lenvatinib together. Avoid or take an alternate drug
plicamycin
When both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
propofol
may enhance the effects of the other by pharmacodynamic synergism
Monitor Closely
pimecrolimus topical
may have an increased immunosuppressive effect when combined with immunosuppressants
reslizumab
may have an increased immunosuppressive effect when combined with immunosuppressants
diroximel fumarate
may have an increased immunosuppressive effect when combined with immunosuppressants
efalizumab
may have an increased immunosuppressive effect when combined with immunosuppressants
triamcinolone
It may enhance the effects when combined with triamcinolone by immunosuppressive effects
abrocitinib
may have an increased immunosuppressive effect when combined with immunosuppressants
avacopan
may have an increased immunosuppressive effect when combined with immunosuppressants
siponimod
may have an increased immunosuppressive effect when combined with immunosuppressants
rituximab
additive immunosuppressive effects may raise the risk of severe infections
ipilimumab
when both drugs are combined, there may be an increased risk of infection
bevacizumab
may increase the immunosuppressive effects of each other
denosumab
may enhance the immunosuppressive effects of each other
abrocitinib
may have an increased immunosuppressive effect when combined with immunosuppressants
avacopan
may have an increased immunosuppressive effect when combined with immunosuppressants
siponimod
may have an increased immunosuppressive effect when combined with immunosuppressants
Minor
No data available for drug.
Dosing & Uses
Adult
Pediatric
Geriatric
Drug Interaction
DRUG INTERACTION
ponesimod
&
No Drug Intearction Found. for ponesimod and .
Contraindicated
agmatine
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
mibefradil
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
donepezil (Rx)
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
rivastigmine
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
labetalol
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
agmatine
may have an increased bradycardic effect when combined with ponesimod
mibefradil
may have an increased bradycardic effect when combined with ponesimod
donepezil (Rx)
may have an increased bradycardic effect when combined with ponesimod
rivastigmine
may have an increased bradycardic effect when combined with ponesimod
labetalol
may have an increased bradycardic effect when combined with ponesimod
mibefradil
may have an increased bradycardic effect when combined with ponesimod
indoramin
may have an increased bradycardic effect when combined with ponesimod
minoxidil topical
may have an increased bradycardic effect when combined with ponesimod
tolazoline
may have an increased bradycardic effect when combined with ponesimod
calfactant
may increase the bradycardic effect of bradycardia, causing agents
tizanidine
may increase the bradycardic effect of bradycardia, causing agents
Serious Use Alternative
inamrinone
It may enhance effects when combined with inamrinone by pharmacodynamic synergism
etoposide
when both drugs are combined, there may be a decreased metabolism of etoposide
vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
paclitaxel
when both drugs are combined, the metabolism of paclitaxel decreases when compared with ponesimod
carmustine
when both the drugs are combined, the risk or severity of adverse effects increases
elotuzumab
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
lenvatinib
QTc interval of one another increases on taking ponesimod and lenvatinib together. Avoid or take an alternate drug
plicamycin
When both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
propofol
may enhance the effects of the other by pharmacodynamic synergism
Monitor Closely
pimecrolimus topical
may have an increased immunosuppressive effect when combined with immunosuppressants
reslizumab
may have an increased immunosuppressive effect when combined with immunosuppressants
diroximel fumarate
may have an increased immunosuppressive effect when combined with immunosuppressants
efalizumab
may have an increased immunosuppressive effect when combined with immunosuppressants
triamcinolone
It may enhance the effects when combined with triamcinolone by immunosuppressive effects
abrocitinib
may have an increased immunosuppressive effect when combined with immunosuppressants
avacopan
may have an increased immunosuppressive effect when combined with immunosuppressants
siponimod
may have an increased immunosuppressive effect when combined with immunosuppressants
rituximab
additive immunosuppressive effects may raise the risk of severe infections
ipilimumab
when both drugs are combined, there may be an increased risk of infection
bevacizumab
may increase the immunosuppressive effects of each other
denosumab
may enhance the immunosuppressive effects of each other
abrocitinib
may have an increased immunosuppressive effect when combined with immunosuppressants
avacopan
may have an increased immunosuppressive effect when combined with immunosuppressants
siponimod
may have an increased immunosuppressive effect when combined with immunosuppressants
Minor
Actions and Spectrum
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Administration
Patient Information Leaflet
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet